- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05184738
Nutritional Supplements in Patients With Anorexia Nervosa (PEPTIDICAN21)
July 1, 2022 updated by: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Evaluation of the Tolerance of Two Oral Nutritional Supplements in Patients With Anorexia Nervosa
Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes.
It is often necessary to supplement the diet of patients with nutritional formulas.
The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Main objective:
• To compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit.
Secondary Objectives:
- Assess the gastrointestinal tolerance of the oral nutritional supplement on a single occasion with respect to a continuous intake over a period of 4 weeks.
- Evaluate the impact of oral nutritional supplementation on nutritional status over a four-week period.
- Evaluate the impact of oral nutritional supplementation on the functional capacity of the patient in a period of four weeks.
- Evaluate the impact of oral nutritional supplementation on the patient's body composition over a four-week period.
- Evaluate the impact of oral nutritional supplementation on the quality of life of the patient in a period of four weeks.
- Evaluate the impact of oral nutritional supplementation on the depressive and anxious symptoms of the patient in a period of four weeks.
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Malaga
-
Málaga, Malaga, Spain, 29009
- Hospital Regional Universitario de Málaga
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 40 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female participants, ≥ 12 y ≤ 40 years of age at screening
- Diagnosed of Anorexy nervous according to DSM-5
- Appropiate cultural level & understanding of the clinical study
- To be in agreement in participate voluntarily in the study and written informed consent must be obtained from the participants.
- Females who are non-pregnant and non-lactating women or women who have given birth at least six weeks before to the screening visit.
Exclusion Criteria:
- Allergy or intolerance to any component of the products under study.
- Participation in a concomitant trial that conflicts with this study
- Doesn't sign the informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oligomeric nutritional formula arm (Bi1 peptidic)
Individuals will receive a Oligomeric nutritional formula.
|
Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
|
OTHER: Standard arm
Individuals will receive a Standard nutritional formula.
|
Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit.
Time Frame: From baseline to week 1
|
Differences in the score of the questionnaire: "Evaluation questionnaire for gastrointestinal complaints".
This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn.
Each section has a score from 0 to 10, which will be filled in by the patient himself.
|
From baseline to week 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the gastrointestinal tolerance of the oral nutritional supplement on a single occasion with respect to a continuous intake over a period of 4 weeks.
Time Frame: From baseline to week 1 in group 1; from baseline to week 8 in group 2
|
Difference in score in the questionnaire "Evaluation questionnaire for gastrointestinal complaints".
This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn.
Each section has a score from 0 to 10, which will be filled in by the patient himself.
|
From baseline to week 1 in group 1; from baseline to week 8 in group 2
|
Compare the sensory perception of a polymeric nutritional supplement with respect to an oligomeric one.
Time Frame: From baseline to week 1 in group 1; from baseline to week 8 in group 2
|
Change in the score of the "Product sensory evaluation questionnaire".
It consists of 11 items, which assess how the patient perceives the organoleptic characteristics of the product and their satisfaction after taking it.
Each item consists of a score from 0 to 10 that the patient has to fill in.
The items can refer to positive or negative characteristics of the product, so the level of score in each of them can indicate better or worse characteristics of the product depending on the characteristic in question.
|
From baseline to week 1 in group 1; from baseline to week 8 in group 2
|
Compare adherence to treatment in group 2 subjects.
Time Frame: From baseline to week 8 in group 2
|
Adherence will be determined by daily registration of the percentage they take of the supplement.
|
From baseline to week 8 in group 2
|
Evaluate the intake of natural food in group 2 patients.
Time Frame: From baseline to week 8 in group 2
|
Dietary registration of natural food intake at breakfast, mid-morning snack and lunch, in group 2 patients.
It will be done through the DIETSTAT program.
The total amount of calories and the percentage of macronutrients will be determined.
|
From baseline to week 8 in group 2
|
Changes in weight
Time Frame: From baseline to week 8
|
Weight will be measured in kg
|
From baseline to week 8
|
Change in hand grip strength
Time Frame: From baselilne to week 8
|
It will be determined with a JAMAR dynamometer.
The mean and maximum of three measurements made on the dominant hand and the mean and maximum of three measurements made on the non-dominant hand will be taken.
The outside will be measured in kg.
|
From baselilne to week 8
|
Change in fat mass
Time Frame: From baselilne to week 8
|
Determined by AKERN bioimpedance analyzer and measured in kg
|
From baselilne to week 8
|
Change in lean mass
Time Frame: From baselilne to week 8
|
Determined by AKERN bioimpedance meter and measured in kg
|
From baselilne to week 8
|
Change in extracellular water
Time Frame: From baselilne to week 8
|
Determined by AKERN bioimpedance analyzer and measured in l
|
From baselilne to week 8
|
Change in intracellular water
Time Frame: From baselilne to week 8
|
Determined by AKERN bioimpedance analyzer and measured in l
|
From baselilne to week 8
|
Change in phase angle
Time Frame: From baselilne to week 8
|
Determined by AKERN bioimpedance analyzer and measured in degrees of angle
|
From baselilne to week 8
|
Change in total cell mass
Time Frame: From baselilne to week 8
|
Determined by AKERN bioimpedance analyzer and measured in kg
|
From baselilne to week 8
|
Evaluate the impact of oral nutritional supplementation on the quality of life of the patient
Time Frame: From baselilne to week 8
|
Changes in the score of the "SF-12 Health Questionnaire" questionnaire.
This questionnaire is the adaptation made for Spain of the SF-12 Health Survey.
The SF-12 is a shortened version of the SF-36 Health Questionnaire designed for uses where it is too long.
Provides a health status profile.
It consists of 12 items from the 8 dimensions of the SF-36 Physical Function (2), Social Function (1), Physical role (2), Emotional role (2), Mental health (2), Vitality (1), Body pain (1), General Health (1).
The response options form Likert-type scales that assess intensity or frequency.
The number of answer options ranges from three to six, depending on the item.
For each of the 8 dimensions, the items are coded, added and transformed on a scale that ranges from 0 (the worst health status for that dimension) to 100 (the best health status).
|
From baselilne to week 8
|
Changes in eating habits and styles
Time Frame: From baselilne to week 8
|
Changes in the score of the "Eating Disorder Examination-Q (EDE-Q)" test.
This questionnaire takes about 10 minutes to complete.
It studies the scope and severity of the characteristics associated with the diagnosis of eating disorder.
It includes 4 subscales: Restriction-diet, Preoccupation with food, Preoccupation with weight and Concern about the figure.
Includes a definition of the term "binge" (eg, "episodes in which you have eaten an abnormally large amount of food under the circumstances" and experiencing a "loss of control" over eating).
The EDE-Q generates two types of data: frequency data on key behavioral features of eating disorders in terms of number of episodes of the behavior, and subscale scores reflecting the severity of characteristics of eating disorders.
Higher scores on the global scale and subscales denote more problematic eating behaviors and attitudes.
|
From baselilne to week 8
|
Assess the impact of oral nutritional supplementation on the patient's depressive and anxious symptoms.
Time Frame: From baseline to week 8
|
Changes in the score of the "Hospital Anxiety and Depression Scale (HADS)".
This aims to detect depressive and anxiety disorders in non-psychiatric hospital services, avoiding overlap with symptoms due to physical illness, without taking into account the physical aspects that may accompany anxiety / depression, only affecting the emotional ones.
It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them.
Based on the score obtained, patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (≥ 11).
The score is referred to the last week.
|
From baseline to week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gabriel MD Olveira, PhD, Hospital Regional Universitario de Málaga, FIMABIS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 15, 2021
Primary Completion (ACTUAL)
March 15, 2022
Study Completion (ANTICIPATED)
September 1, 2022
Study Registration Dates
First Submitted
December 2, 2021
First Submitted That Met QC Criteria
December 22, 2021
First Posted (ACTUAL)
January 11, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 5, 2022
Last Update Submitted That Met QC Criteria
July 1, 2022
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEPTIDIC-AN-2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anorexia Nervosa
-
Rosemary Claire RodenChildren's Miracle NetworkEnrolling by invitationBulimia Nervosa | Impulsive Behavior | Purging (Eating Disorders) | Eating Disorders | Eating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia in Adolescence | Anorexia Nervosa, Atypical | Anorexia Nervosa, Binge Eating/Purging TypeUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Fundació La Marató de TV3RecruitingAnorexia Nervosa | Anorexia Nervosa in Remission | Anorexia Nervosa Restricting TypeSpain
-
Duke UniversityCompletedAdolescent Anorexia Nervosa | Subthreshold Anorexia NervosaUnited States
-
University of California, San DiegoRecruitingAnorexia Nervosa | Bulimia Nervosa | Atypical Anorexia Nervosa | Atypical Bulimia NervosaUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH) and other collaboratorsCompletedAnorexia Nervosa | Anorexia | Eating Disorder | Eating Disorders in Adolescence | Anorexia in Adolescence | Anorexia Nervosa, Atypical | Anorexia Nervosa Restricting Type | Anorexia in ChildrenUnited States
-
Linnaeus UniversityGöteborg University; Linkoeping UniversityRecruitingBulimia Nervosa | Major Depression | Anorexia Nervosa/BulimiaSweden
-
Umeå UniversityActive, not recruitingAnorexia Nervosa | Anorexia in Adolescence | Anorexia Nervosa, AtypicalSweden
-
Yeshiva UniversityYale UniversityRecruitingAnorexia Nervosa | Bulimia Nervosa | Anorexia Nervosa, Atypical | Bulimia; AtypicalUnited States
-
The Miriam HospitalUnknownEating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia Nervosa Restricting TypeUnited States
-
University of California, San DiegoRecruitingAnorexia Nervosa | Atypical Anorexia NervosaUnited States
Clinical Trials on Experimental Treatment, Oligomeric nutritional formula
-
Brno University HospitalRecruitingEnteral Feeding IntoleranceCzechia
-
Abbott NutritionCompletedDiabetes Mellitus, Type 2Russian Federation
-
Abbott NutritionCompleted
-
Brno University HospitalMasaryk UniversityRecruiting
-
Hasanuddin UniversityCompletedCritically Ill | Intensive Care UnitIndonesia
-
Abbott NutritionCompletedDiabetes Mellitus, Type 2United States
-
Abbott NutritionCompletedInfant, NewbornUnited States
-
Société des Produits Nestlé (SPN)CompletedFeeding DisorderPhilippines, Hong Kong, Taiwan, Thailand
-
Abbott NutritionCompleted
-
Abbott NutritionCompleted